110 related articles for article (PubMed ID: 24676028)
21. Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease.
Lim WLF; Huynh K; Chatterjee P; Martins I; Jayawardana KS; Giles C; Mellett NA; Laws SM; Bush AI; Rowe CC; Villemagne VL; Ames D; Drew BG; Masters CL; Meikle PJ; Martins RN;
J Alzheimers Dis; 2020; 76(1):303-315. PubMed ID: 32474467
[TBL] [Abstract][Full Text] [Related]
22. Rubidium and potassium levels are altered in Alzheimer's disease brain and blood but not in cerebrospinal fluid.
Roberts BR; Doecke JD; Rembach A; Yévenes LF; Fowler CJ; McLean CA; Lind M; Volitakis I; Masters CL; Bush AI; Hare DJ;
Acta Neuropathol Commun; 2016 Nov; 4(1):119. PubMed ID: 27842602
[TBL] [Abstract][Full Text] [Related]
23. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD;
J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723
[TBL] [Abstract][Full Text] [Related]
24. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
25. Zinc in Alzheimer's Disease: A Meta-Analysis of Serum, Plasma, and Cerebrospinal Fluid Studies.
Ventriglia M; Brewer GJ; Simonelli I; Mariani S; Siotto M; Bucossi S; Squitti R
J Alzheimers Dis; 2015; 46(1):75-87. PubMed ID: 25697706
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
27. Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative.
Ellis KA; Rowe CC; Villemagne VL; Martins RN; Masters CL; Salvado O; Szoeke C; Ames D;
Alzheimers Dement; 2010 May; 6(3):291-6. PubMed ID: 20451879
[TBL] [Abstract][Full Text] [Related]
28. Homeostasis of metals in the progression of Alzheimer's disease.
González-Domínguez R; García-Barrera T; Gómez-Ariza JL
Biometals; 2014 Jun; 27(3):539-49. PubMed ID: 24668390
[TBL] [Abstract][Full Text] [Related]
29. Aβ1-17 is a major amyloid-β fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease.
Pérez-Grijalba V; Pesini P; Allué JA; Sarasa L; Montañés M; Lacosta AM; Casabona D; San-José I; Boada M; Tárraga L; Ruiz A; Sarasa M
J Alzheimers Dis; 2015; 43(1):47-56. PubMed ID: 25061046
[TBL] [Abstract][Full Text] [Related]
30. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.
Lui JK; Laws SM; Li QX; Villemagne VL; Ames D; Brown B; Bush AI; De Ruyck K; Dromey J; Ellis KA; Faux NG; Foster J; Fowler C; Gupta V; Hudson P; Laughton K; Masters CL; Pertile K; Rembach A; Rimajova M; Rodrigues M; Rowe CC; Rumble R; Szoeke C; Taddei K; Taddei T; Trounson B; Ward V; Martins RN; AIBL Research Group
J Alzheimers Dis; 2010; 20(4):1233-42. PubMed ID: 20413897
[TBL] [Abstract][Full Text] [Related]
31. Blood-based protein biomarkers for diagnosis of Alzheimer disease.
Doecke JD; Laws SM; Faux NG; Wilson W; Burnham SC; Lam CP; Mondal A; Bedo J; Bush AI; Brown B; De Ruyck K; Ellis KA; Fowler C; Gupta VB; Head R; Macaulay SL; Pertile K; Rowe CC; Rembach A; Rodrigues M; Rumble R; Szoeke C; Taddei K; Taddei T; Trounson B; Ames D; Masters CL; Martins RN; ;
Arch Neurol; 2012 Oct; 69(10):1318-25. PubMed ID: 22801742
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
Lewczuk P; Popp J; Lelental N; Kölsch H; Maier W; Kornhuber J; Jessen F
J Alzheimers Dis; 2012; 28(1):119-25. PubMed ID: 21971403
[TBL] [Abstract][Full Text] [Related]
33. Personal memory function in mild cognitive impairment and subjective memory complaints: results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing.
Buckley RF; Saling MM; Irish M; Ames D; Rowe CC; Lautenschlager NT; Maruff P; Macaulay SL; Martins RN; Masters CL; Rainey-Smith SR; Rembach A; Savage G; Szoeke C; Ellis KA
J Alzheimers Dis; 2014; 40(3):551-61. PubMed ID: 24496075
[TBL] [Abstract][Full Text] [Related]
34. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
35. Genome instability biomarkers and blood micronutrient risk profiles associated with mild cognitive impairment and Alzheimer's disease.
Lee SL; Thomas P; Fenech M
Mutat Res; 2015 Jun; 776():54-83. PubMed ID: 26364206
[TBL] [Abstract][Full Text] [Related]
36. Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation.
Hare DJ; Doecke JD; Faux NG; Rembach A; Volitakis I; Fowler CJ; Grimm R; Doble PA; Cherny RA; Masters CL; Bush AI; Roberts BR
ACS Chem Neurosci; 2015 Mar; 6(3):398-402. PubMed ID: 25588002
[TBL] [Abstract][Full Text] [Related]
37. Oxidative stress and APO E polymorphisms in Alzheimer's disease and in mild cognitive impairment.
Chico L; Simoncini C; Lo Gerfo A; Rocchi A; Petrozzi L; Carlesi C; Volpi L; Tognoni G; Siciliano G; Bonuccelli U
Free Radic Res; 2013 Aug; 47(8):569-76. PubMed ID: 23668794
[TBL] [Abstract][Full Text] [Related]
38. Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability.
Baum L; Chan IH; Cheung SK; Goggins WB; Mok V; Lam L; Leung V; Hui E; Ng C; Woo J; Chiu HF; Zee BC; Cheng W; Chan MH; Szeto S; Lui V; Tsoh J; Bush AI; Lam CW; Kwok T
Biometals; 2010 Feb; 23(1):173-9. PubMed ID: 19911117
[TBL] [Abstract][Full Text] [Related]
39. Combination of plasma tumor necrosis factor receptors signaling proteins, beta-amyloid and apolipoprotein E for the detection of Alzheimer's disease.
Zhang J; Jia J; Qin W; Wang S
Neurosci Lett; 2013 Apr; 541():99-104. PubMed ID: 23500026
[TBL] [Abstract][Full Text] [Related]
40. Increased protein-conjugated acrolein and amyloid-β40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease.
Waragai M; Yoshida M; Mizoi M; Saiki R; Kashiwagi K; Takagi K; Arai H; Tashiro J; Hashimoto M; Iwai N; Uemura K; Igarashi K
J Alzheimers Dis; 2012; 32(1):33-41. PubMed ID: 22751175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
